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The high costs of getting ethical and site-
specific approvals for multi-centre research
Adrian G. Barnett1*, Megan J. Campbell1, Carla Shield1, Alison Farrington1, Lisa Hall1, Katie Page1, Anne Gardner2,
Brett G. Mitchell3 and Nicholas Graves1
Abstract
Background: Multi-centre studies generally cost more than single-centre studies because of larger sample sizes
and the need for multiple ethical approvals. Multi-centre studies include clinical trials, clinical quality registries,
observational studies and implementation studies. We examined the costs of two large Australian multi-centre
studies in obtaining ethical and site-specific approvals.
Methods: We collected data on staff time spent on approvals and expressed the overall cost as a percent of the
total budget.
Results: The total costs of gaining approval were 38 % of the budget for a study of 50 centres (mean cost AUD
$6960 per site) and 2 % for a study of 11 centres (mean cost AUD $2300 per site). Seventy-five and 90 % of time
was spent on repeated tasks, respectively, and many time-consuming tasks, such as reformatting documents, did
nothing to improve the study design or participant safety.
Conclusions: Improvements have been made to the ethical approval application system, but more gains could
be made without increasing risks of harm to research participants. We propose that ethical review bodies and
individual sites publish statistics on how long they take to process approvals which could then be nationally
benchmarked.
Keywords: Research ethics, Ethical review, Multi-centre study, Australia
Background
An increasingly popular study design is a multi-centre
study, in which a study protocol is simultaneously run
over multiple sites. Many multi-centre studies are clin-
ical trials, but they can also be quasi-experimental
designs such as a pre-post design investigating the im-
pact of a change in practice, or implementation studies
examining how a proven implementation works at
multiple sites, or clinical quality registries that collate
routine outcome data from multiple sites.
Searching PubMed, there were 614 papers with
“multi-centre trial/study” in the title in 2005 (including
US spelling and no hyphen) and 1248 papers in 2015,
which is a doubling in published multi-centre studies in
10 years. In the international clinical trials registry
ClinicalTrials.gov, there were 1235 multi-centre studies
registered to begin recruitment in 2005, and 2418 in
2015 (a 96 % growth). This rapid growth in multi-
centre research was acknowledged by the chair of the
Australian Health Ethics Committees [1].
Two common reasons for needing a multi-centre
study are (1) to increase generalisability by including
sites in multiple locations and/or of multiple types, for
example, private and public hospitals in every county,
state or province, and (2) where the site is the unit of
randomisation and hence multiple sites are needed to pro-
vide adequate statistical power, for example, an interven-
tion to reduce falls that applies to the whole hospital.
To ensure research on humans is ethically conducted,
researchers must submit their detailed research plans to
an ethical review body. In Australia, the submission re-
quires multiple forms, including, but not limited to:* Correspondence: a.barnett@qut.edu.au
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 A main application form such as the National
Ethics Application Form (or NEAF) with questions
on risk to participants and data security
 The consent form for participants
 The forms used to engage participants
(e.g. information sheets, recruitment materials)
 All surveys or detailed protocols for clinical data
or specimen collection
The ethical review body decides if the research meets
the requirements of the Australian National Statement
on Ethical Conduct in Human Research and is ethically
acceptable [2]. In Australia, in addition to ethical re-
view, there is a governance process carried out by each
institution that permits research to be conducted under
their auspices. In public health organisations, this is
referred to as site-specific assessment and involves a
separate set of forms. The application forms vary by
site, but generally include details on recruitment, vul-
nerable groups, data security, resource use, budgets and
legal implications. Both the ethics and site-specific
forms usually require multiple signatures from the re-
searchers, senior staff at their institution, and executive
leaders at each participating site.
Additional ethics applications (to an ethical review
body) are required for each site in a multi-centre study
that is not covered by the initial ethics application. This
is then followed by further site-specific approvals for
each study site. Therefore, the more sites that are
recruited the greater the ethics preparation time needed
before the study can start. Since 2007, New South Wales
allows one ethical review body to give multi-centre eth-
ics approval [3]. In 2013, a “national” mutual acceptance
scheme for single ethical review of multi-centre clinical
trials was adopted by four states (New South Wales,
Queensland, South Australia and Victoria). In 2015, the
scheme was expanded to include all human research,
although there are a number of important exceptions
including projects requiring access to state-wide data
collections, and research at universities and private
hospitals. In Australia and in many other countries, all
multi-centre studies must still complete multiple site-
specific approval applications.
Our research team has recently managed two large
national multi-centre studies and wanted to share our
experience with the research community. We are con-
cerned that the current process of getting ethical and
site-specific approval is overly costly in terms of staff
and time, and does not lead to any benefit, such as re-
ducing risk for participants, as much of the time is
spent on repeat applications [4]. Previous studies have
examined the time taken for ethical review, and a re-
cent international scoping review found 54 studies that
examined the time taken and over 20 studies that
examined costs [5]. We present two case studies and
estimate the percent of the research budget spent on
ethical and site-specific approvals.
Methods
We examined the ethical and site-specific procedures
for two multi-centre studies funded by the Australian
National Health and Medical Research Council
(NHMRC). The characteristics of the two studies are
in Table 1. The NHHE was an observational study of
hand hygiene practices in 50 hospitals. REACH was a
stepped-wedged randomised trial of a cleaning inter-
vention to reduce hospital-acquired infection in 11
hospitals. As neither study was a clinical trial, a mu-
tual acceptance process was not available. Complete
details on both studies are available in their protocol
papers [6, 7].
We aimed to estimate the total time spent on getting
ethical and site-specific approval both in terms of staff
time and calendar time. We did not consider the time
spent by the chief investigators writing the protocol or
original grant application because our focus was on the
approval process and the impact on the study budget.
For the REACH Trial, we prospectively collected data
by asking staff members to note their time spent on
ethical and site-specific approvals using an Excel
spreadsheet with times split by each ethical review body
and site. Ethics tasks included completing the applica-
tion form, changing documents (logos, ethics com-
plaints statements, footers), uploading documents to
web sites, and email and phone conversations with eth-
ical review body staff on application requirements (for
documents, signatures). Site-specific tasks included
completing the separate application form, changing
documents (footers), uploading documents to web sites,
and email and phone conversations with RGO staff on
application requirements (for documents, signatures).
For the REACH Trial, we also recorded the dates of
the start and end of the application process for each site.
The start date was the date we started preparing the ap-
plication. The end date was when approval was granted,
including the time needed for any additional requests
(e.g. confidentially agreements).
For the National Hand Hygiene Evaluation, we used a
retrospective estimate of cost based on the staff mem-
bers involved and the percentages of their time spent on
ethics and site-specific applications.
For both studies, the cost estimates are relatively sim-
ple. We estimated the total time and salary costs and
expressed the costs as a percent of the overall study
budget. We estimated the proportion of time spent on
repeat applications, that is, any time not on the original
ethical or site-specific application.
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Results
The staff members and the percentages of their times on
approvals are in Table 2. Four staff members worked on
the National Hand Hygiene Evaluation. The overall cost
of getting approvals was an estimated AUD $348,000 or
38 % of the total study budget. One notable application
was for an ethical review body that required 30 hard
copies of the application paperwork, including the 200-
page NEAF application—over 7000 pages in total—and
this ethical review body was aware that the application
had already been approved by another ethical review
body. An estimated 25 % of time was spent on the ori-
ginal ethics application, with 75 % on repeated applica-
tions. The planned timeline for ethical and site-specific
approval underestimated the actual time by 17 months.
Two staff members were used for the REACH Trial
(Table 2). The overall costs were estimated as AUD
$25,000 or 2 % of the total study budget. Just 10 % of
time was spent on the original ethics application, with
the remaining 90 % on repeat ethics forms and site-
specific approvals.
The calendar times of the applications for the REACH
Trial are in Fig. 1. The overall process took 313 days,
starting on 27 August 2015 and ending on 4 July 2016.
The shortest approval time was 23 days for Hospital 6
and the longest was 229 days for Hospital 11, which is
almost 10 times longer than the shortest. We printed
over 2000 pages of application hard copy forms and 220
pages were electronic. Our planned time line for ethical
and site-specific approval underestimated the actual time
by 6 months.
The mean cost per site was AUD $2300 for REACH
and AUD $6960 for the National Hand Hygiene study.
Discussion
Our results show the potentially high costs of running
multi-centre studies that require multiple approvals.
Similarly, high costs in Australia were found by a multi-
centre registry [8] and a multi-centre low risk observa-
tional study [9].
The costs were particularly high for the National Hand
Hygiene Evaluation which covered 50 hospitals across 8
states and territories and needed 38 % of the budget,
whereas the REACH Trial with 11 hospitals across 7
states and territories needed 2 % of the budget. Both
studies were mostly low risk; high risk multi-centre stud-
ies could expect higher costs and longer delays [7]. Most
of our staff members had experience with ethics applica-
tions, and studies using less experienced staff would
likely experience longer delays. For NHHE, the work on
ethical processes continued into the third year and for
REACH into the second year, highlighting that this
process is unlikely to be completed in the first year. Our
original timelines for both studies underestimated the
amount of time needed by at least 6 months. The delays
meant that both projects had to apply to the funding
agency for a timeline extension.
Table 1 Characteristics of the two studies and the ethical requirements
Short title National Hand Hygiene Evaluation (NHHE) REACH Trial
Full title Evaluating hand hygiene interventions
and their ability to reduce healthcare associated infection
REACH: Researching Effective Approaches
to Cleaning in Hospitals
Total funding (AUD) $908,849 $1,146,817
Study years 2010–2013 2014–2017
Study design Observational Stepped-wedge randomised trial
Number of hospitals 50 11
States/territories 8 7
Number of ethical review bodies 24 11
Ethical risk category High risk in Queensland (9 sites) and low risk in others Low risk in all sites
Table 2 Staff time and salary spent on ethical and site-specific











N1 Year 1 1322 81
Year 2 353 23




Year 2 1410 66
N3 Year 3 1763 81
N4 Year 3 881 41
Total 6786 348
REACH Trial R1 Year 1 113 6




Year 2 (PT) 348 13
Total 601 25
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A number of processes created difficulties for both
studies. One was the frequent change in regulatory staff
which slowed the approval process when e-mails to
staff who had left were lost and new staff needed time
to become acquainted with our study. There was also
variability in the speed with which regulatory staff
responded to both general enquiries and submitted
applications, possibly due to their experience and work-
load. Lack of clear, consistent or available guidelines for
application requirements also hindered the process.
Much of our time was spent on repetitive and low value
tasks, such as reformatting documents for each new
ethical review body’s requirements, uploading these
documents to web sites, and obtaining signatures from
researchers who had already signed multiple previous
applications. These tasks incur costs and return no
benefits in terms of improved study design or partici-
pant safety. Interestingly, the site-specific approval
often took longer than the ethics application (Fig. 1),
which is disappointing given that this process was de-
signed to streamline the approval process.
In the REACH Trial, which could only commence
once all sites had all required governance approvals, the
variation in ethical review body processes and timings,
and the unpredictable nature of the approval process,
delayed trial commencement. The associated and pro-
tracted uncertainty of trial commencement was an issue
for sites that had agreed early to participate and had
already completed their approvals. In addition, staff costs
continued throughout the extended approval process,
with associated budget impact on trial implementation.
A key reason why REACH cost less than NHHE was
because there were far fewer sites (11 compared with
50) and all REACH sites were classified as low risk
whereas some NHHE sites were deemed to be high
risk by some ethical review bodies. However, the
REACH study was also cheaper per site. This could be
because we employed a research assistant dedicated to
leading the governance processes, and because of the
lessons our research team learned in the earlier NHHE
study. However, a recent study of using an ethics offi-
cer to speed applications found no impact on approval
times [10]. There may also have been some streamlin-
ing of ethical processes over time, with some ethical
review bodies and sites actively seeking to make the
process easier for researchers.
It could be argued that the time and money was well
spent as the public need to be protected from unethical
research. However, for both studies, the majority of the
time was spent on repeat applications. For the National
Hand Hygiene Evaluation project, a third of the budget,
AUD $348,000 was spent obtaining approval for a study
that simply involved surveying nurses about their hand
hygiene behaviour. Two of the 50 hospitals identified
our research as quality improvement and asked us not
to submit a HREC application as it would waste time,
whereas another ethical review body required over 7000
pages of documentation.
Fig. 1 Application times by calendar date for the REACH Trial for the 12 hospitals (August 2015 to July 2016). One hospital was withdrawn.
Two hospitals (7 and 10) did not need site-specific approval, one because the details were covered in the ethics forms and the other simply
did not require a SSA. One ethics approval covered two sites
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Our estimates only consider the costs of the research
team and not the time of staff at the study sites, ethical
review bodies or research governance offices. Nor did
we include the financial charges made by some ethical
review bodies, for example one charged AUD $660 for
the REACH Trial application. We also did not include
printing costs or the costs of post-approval monitoring.
We also did not include the time spent by the chief in-
vestigators writing the protocols or ethical applications.
We also only examined overall costs and did not break
down the costs into detailed activities as that data was
not available.
The estimates for the NHHE were retrospective, and
although good records were available on the staff
employed and their pay scales, we had to estimate their
percent time commitment spent on ethical approvals.
An established problem
Concern about the time taken for ethical approval is a
long-standing issue that has been raised in journals, pol-
icies and forums [11–13]. For example, a UK study in
1996 found a similar variability in times to our REACH
Trial, as 36 ethical review bodies took between 6 and
208 days [14]. Previous studies have also highlighted the
widely varying requirements of ethical review bodies for
the same study, and discussed how the burden of ethical
processes stymies new research [15, 16]. High costs and
long delays have occurred for all types of study designs,
including clinical trials [17], observational studies [9]
and clinical quality reviews [8].
In 2007, the Australian National Statement on Ethical
Conduct in Human Research stated that, “each institu-
tion has the further responsibility to adopt a review
process that eliminates any unnecessary duplication of
ethical review” [2]. Soon after the NHMRC established
the Harmonisation of Multi-centre Ethical Review
(HoMER) project to try and implement a national ap-
proach to multi-centre research. An NHMRC-hosted
national forum on clinical trial research governance in
2013 included calls for “streamlining of ethical review pro-
cesses” and more efficient site-specific approvals, and con-
cluded that better systems should increase Australia’s
international competitiveness in clinical trials.
Recommendations for researchers
Researchers conducting multi-centre studies could pro-
spectively collect the total staff time spent on ethics and
site-specific applications. If enough researchers shared
this data with our team we could use a meta-analysis to
estimate the average cost per study. We could then ex-
trapolate this cost to a national figure that would likely
get more political attention than one or two case stud-
ies. Given that an estimated 85 % of current research
effort is wasted [18], this figure would be part of a
larger debate about increasing the value of health and
medical research.
Researchers applying for funding for multi-centre trials
should ensure their budget includes funding for ethics
applications with costs and a timeline that is propor-
tional to the number of centres. Research plans should
consider the potential time lag for gaining all approvals
and associated impact on trial timings and budgets, es-
pecially where commencement of the trial is contingent
on all approvals at each site being completed. Re-
searchers acting as grant reviewers need to be accommo-
dating of these long time lines and large budgets.
Recommendations for improvement
The Australian Government Office for Learning and
Teaching commissioned a report into delays in ethical
approvals [19], which recommended, “An efficient ar-
rangement for the ethical review of research that has
already been ethically reviewed by another institution”.
Similarly, a study that considered the variation in deci-
sions of ethical review bodies recommended that after
the initial review any subsequent reviews of the same ap-
plication must be expedited [20]. We strongly support
this idea, and this makes sense as the judgement of the
original review should be trusted. However, we note that
there has been strong support for this idea from re-
searchers and the NHMRC for some time and it has yet
to be fully implemented and does not cover site-specific
approvals.
The roll-out in 2016 of the new Health Research
Authority approval in England shows that reforms to in-
crease efficiency of multi-centre studies are possible
[21]. This streamlined process replaced the need for
local checks of legal compliance, which is particularly
time-saving for multi-centre research. It was piloted to
iron out issues, and it publishes regular statistics on the
number of applications received and turn-around times.
Relatively simple efficiencies could also be made to the
application forms as much of the information on the
site-specific form is already in the ethical application.
A key issue is that ethical review bodies are heavily
incentivised to reduce risk, rather than save costs for ap-
plicants. They are able to externalise costs to those ap-
plying for ethical approval in pursuit of some marginal
reduction in risks. It is plausible that risk is not reduced
at all, but the process of extra review and delay provides
an insurance policy against some future unforeseen
event. If costs to applicants were somehow made im-
portant to ethical review bodies, they might reassess the
speed and scope of their work.
National statistics on review times
We suggest publishing statistics on the time taken for
ethical review for every ethical review body and site on a
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national web page. The statistics would be based on na-
tionally consistent definitions of when the review started
and ended. This would allow benchmarking and the
identification of review bodies or sites with times that
are significantly longer than the typical distribution of
times. Our results (Fig. 1) show a large variability, which
suggests that national statistics could also show import-
ant variability. Results could be stratified by the applica-
tions’ risk level (administrative, low and high).
If an ethical review body or site had relatively long re-
view times, then this could be used to identify problems
and provide assistance. Advice could be sought from
those ethical review bodies and sites with relatively fast
times. We acknowledge that people working on ethical
review bodies provide their time voluntarily, and they
often have to read multiple applications from a wide var-
iety of fields and consider difficult ethical questions that
may be poorly communicated or considered by the re-
searchers (leading to delays that are outside the control
of the ethical review body). However, one way to reduce
their workload is to avoid assessing studies that have
already been approved by other bodies.
National statistics on times would allow researchers to
better plan how long their applications would take.
Some health and medical journals publish similar statis-
tics to fully inform researchers about the expected peer
review time.
A national web site of ethical review body times would
need financial support and require time from staff at the
ethical review bodies. However, given such data are al-
most wholly electronic, the burden should be minimal,
indeed it may already be possible to create these statis-
tics from national online ethics forms.
Conclusions
This paper adds to the evidence demonstrating the high
costs of getting ethical and site-specific approval for
multi-centre research. Perhaps we should be resigned to
multi-centre applications taking longer than 12 months
and build in the costs and times to our research projects.
But this means that health improvements are being de-
layed and funding is being reduced for other research.
The public would likely be unhappy at precious research
dollars being spent on tasks that delay discovery for no
benefit. We think the current systems could be stream-
lined without any increased risk to public safety.
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